首页> 美国卫生研究院文献>other >Genomic and Proteomic Characterizations of Sfin-1 a Novel Lytic Phage Infecting Multidrug-Resistant Shigella spp. and Escherichia coli C
【2h】

Genomic and Proteomic Characterizations of Sfin-1 a Novel Lytic Phage Infecting Multidrug-Resistant Shigella spp. and Escherichia coli C

机译:Sfin-1的基因组和蛋白质组学表征一种新型的可感染耐多药志贺氏菌的噬菌体。和大肠杆菌C

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Shigellosis is a public health threat in developed as well as developing countries like “India.” While antibiotic therapy is the mainstay of treatment for shigellosis, current emergence of multidrug-resistant strains of Shigella spp. has posed the problem more challenging. Lytic bacteriophages which destroy antibiotic resistant Shigella spp. have great potential in this context and hence their identification and detailed characterization is necessary. In this study we presented the isolation and a detailed characterization of a novel bacteriophage Sfin-1, which shows potent lytic activity against multidrug-resistant isolates of Shigella flexneri, Shigella dysenteriae, Shigella sonnei obtained from clinical specimens from shigellosis patients. It is also active against Escherichia coli C. The purified phage is lytic in nature, exhibited absorption within 5–10 min, a latent period of 5–20 min and burst size of ∼28 to ∼146 PFU/cell. The isolated phage shows stability in a broad pH range and survives an hour at 50°C. Genome sequencing and phylogenetic analyses showed that Sfin-1 is a novel bacteriophage, which is very closely related to T1-like phages (89.59% identity with Escherichia virus T1). In silico analysis indicates that Sfin-1 genome consists of double stranded linear DNA of 50,403 bp (GC content of 45.2%) encoding 82 potential coding sequences, several potential promoters and transcriptional terminators. Under electron microscopy, Sfin-1 shows morphology characteristics of the family Siphoviridae with an isometric head (61 nm) and a non-contractile tail (155 nm). This is most likely the first report of a lytic bacteriophage that is active against three of the most virulent multidrug-resistant Shigella species and therefore might have a potential role in phage therapy of patients infected with these organisms.
机译:志贺氏菌病是发达国家和“印度”等发展中国家的公共卫生威胁。尽管抗生素疗法是志贺菌病的主要治疗手段,但目前出现了志贺氏菌多药耐药菌株。使这个问题更具挑战性。溶菌性噬菌体会破坏抗药性志贺氏菌。在这种情况下具有很大的潜力,因此有必要对其进行识别和详细表征。在这项研究中,我们介绍了新型噬菌体Sfin-1的分离和详细特性,该噬菌体显示了对从志贺氏菌病患者的临床标本中获得的弗氏志贺氏菌,痢疾志贺氏菌,Sonneella sonnei多重耐药菌株的有效裂解活性。它也对大肠杆菌C有活性。纯化的噬菌体本质上是裂解性的,在5-10分钟内表现出吸收,潜伏期5-20分钟,爆发大小为约28至146 PFU /细胞。分离的噬菌体在很宽的pH范围内显示出稳定性,并在50°C下可以存活一个小时。基因组测序和系统发育分析表明,Sfin-1是一种新型噬菌体,与T1类噬菌体(与埃希氏病毒T1的同源性为89.59%)非常相关。电脑分析表明,Sfin-1基因组由50,403 bp(GC含量为45.2%)的双链线性DNA组成,编码82个潜在的编码序列,几个潜在的启动子和转录终止子。在电子显微镜下,Sfin-1表现出具有等长头部(61 nm)和非收缩尾部(155 nm)的剑尾病毒科的形态特征。这很可能是裂解细菌噬菌体的第一个报道,该噬菌体对三种最具毒性的多重耐药志贺氏菌具有活性,因此在感染这些生物的患者的噬菌体治疗中可能具有潜在作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号